David Cooper
Partner
Get their honest, personalized take on your startup.
Sign in to pitch David →At a glance
- Full Name
- David J. Cooper
- Title
- Partner, Quantum Capital Partners Ltd; Principal, DCA
- Firm
- Quantum Capital Partners Ltd; DCA
- Firm Type
- Strategic and financial advisory / active investor
- Target Company Profile
- High-growth companies and technology-based businesses, especially those needing corporate finance, business development, licensing, technology appraisal, IP exploitation, due diligence, strategic alliances, or interim management support.
- Sector Focus
- Healthcare, life sciences, new technology industries
- Geographic Focus
- International, with stated experience across North America, Western and Eastern Europe, the Middle East, Japan, and the Pacific Rim.
- Location
- London, United Kingdom
Background
David J. Cooper is a London-based business development and corporate finance professional. A profile published by Sherman Nigretti identifies him as Principal of DCA, London, and describes him as having more than 35 years of involvement in healthcare, life science, and new technology industries.
Cooper founded DCA, described as a business development practice with an international network of associates. His work has included technology transfer, commercial alliances, new product development, acquisition and divestiture advice, business intelligence, strategic planning, licensing, marketing, IP protection and exploitation, technology appraisal, due diligence, and interim management.
A 2007 SEC filing for NextGen Bioscience Inc. states that Cooper founded DCA in 1974 and had been its principal since then. The same filing says he co-founded Quantum Capital Partners in 2004 and served as a Partner; it describes Quantum as providing strategic and financial advice to high-growth companies and helping larger investment clients source, manage, and exit investment positions.
Kando/VC Datalab lists David Cooper as a Partner at Quantum Capital Partners Ltd. and states that he trained as a scientist and studied Philosophy, Psychology, and Business Studies.
Investment Thesis & Focus
- Focuses on healthcare, life sciences, and new technology companies where business development, corporate finance, IP strategy, licensing, and strategic alliances are material to growth.
- Quantum Capital Partners’ stated role, per the SEC filing, is to provide “strategic and financial advice to high growth companies” and help investment clients “source, manage and exit investment positions.”
- Cooper’s own background points to a hands-on, advisory-led investment style rather than a purely passive capital model: technology appraisal, market due diligence, corporate alliances, and interim management are repeatedly cited as core areas of expertise.
- Best-fit companies are likely emerging or high-growth businesses with defensible technology, clear IP or licensing questions, and a need for commercialisation or international expansion support.
- No independently verified public check size was found.
Notable Investments
- NextGen Bioscience Inc. / Oxon Life Science transaction — In 2007, NextGen Bioscience disclosed an asset-purchase agreement with Oxon Life Science involving cancer-therapy intellectual property; Cooper was proposed as Chairman and director and was expected to hold 2,000,000 post-split shares after the transaction.
- Quantum Capital Partners Ltd investment activity — Kando/VC Datalab lists Quantum Capital Partners Ltd as an active investor and names David Cooper as Partner, but no independently verified public portfolio list tied specifically to Cooper was found.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.